IXHL
Incannex Healthcare Inc
NASDAQ · Pharmaceuticals
$0.29
+0.04 (+15.20%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 24.18M | 25.07M | 24.10M |
| Net Income | 3.50M | 4.81M | 4.53M |
| EPS | — | — | — |
| Profit Margin | 14.5% | 19.2% | 18.8% |
| Rev Growth | +8.0% | +16.3% | +6.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 29.40M | 30.57M | 31.96M |
| Total Equity | 40.14M | 43.10M | 45.37M |
| D/E Ratio | 0.73 | 0.71 | 0.70 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.33M | 6.46M | 6.22M |
| Free Cash Flow | 2.28M | 4.01M | 3.85M |